InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the detailed record of transactions filed by Hirmand Mohammad, Vice-Président Exécutif. Officer active across 1 company, notably Turning Point Therapeutics, Inc.. Cumulatively, 2 filings have been recorded. Breakdown: 0 buy · 1 sell. Total volume traded: €21k. History available since 9 February 2022. The latest transaction was filed on 17 August 2022 (Disposition). Regulator: SEC (Form 4). The full history is openly available.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 条申报中的 2 条
Mohammad Hirmand is the Executive Vice President and Chief Medical Officer at Turning Point Therapeutics, Inc. He is responsible for the medical direction of the company, overseeing the development and implementation of clinical strategies. Hirmand plays a crucial role in therapeutic innovation, aiming to improve treatments for patients. His expertise in medicine and clinical research is a major asset for Turning Point.